ClinicalTrials.gg
CompletedNCT05919693AMARONEUpdated Nov 3, 2026Results posted

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

A Phase 1/2 interventional study of Remigromig in Neovascular Age-related Macular Degeneration (NVAMD) and Diabetic Macular Edema (DME), sponsored by EyeBiotech Ltd.. Completed at 32 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by EyeBiotech Ltd. (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Updated Nov 3, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
312th of 491
33 · median 55
Started
2023
with 23 others
Phase 1/2
61 of 645
7 open now
Registered
548th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 312th largest by enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2023, is one of 61 in phase 1/2, and was the 548th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Read the detailed description

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration (NVAMD)
  • Diabetic Macular Edema (DME)

Keywords

  • Neovascular Age-related Macular Degeneration (NVAMD)
  • Diabetic Macular Edema (DME)
  • Age-related Macular Degeneration (AMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing and able to understand the study procedures and the risks involved and provide written before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye

Exclusion criteria

Exclusion Criteria:

  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Dose 1

    Part 1 MAD Portion Dose 1 - Low Dose

    Drug: Remigromig

  • Experimental
    Dose 2

    Part 1 MAD Portion Dose 2 - Low-Mid Dose

    Drug: Remigromig

  • Experimental
    Dose 3

    Part 1 MAD Portion Dose 3 - Mid-High Dose

    Drug: Remigromig

  • Experimental
    Dose 4

    Part 1 MAD Portion Dose 4 - High Dose

    Drug: Remigromig

  • Experimental
    DME Medium Dose

    Part 2 Naïve DME monotherapy Medium Dose

    Drug: Remigromig

  • Experimental
    DME High Dose

    Part 2 Naïve DME monotherapy High Dose

    Drug: Remigromig

  • Experimental
    Naïve NVAMD Medium Dose

    Part 2 Naïve NVAMD combination therapy Medium Dose

    Drug: Remigromig

  • Experimental
    Naïve NVAMD High Dose

    Part 2 Naïve NVAMD combination therapy High Dose

    Drug: Remigromig

  • Experimental
    Experienced NVAMD Medium Dose

    Part 2 Experienced NVAMD combination therapy Medium Dose

    Drug: Remigromig

  • Experimental
    Experienced NVAMD High Dose

    Part 2 Experienced NVAMD combination therapy High Dose

    Drug: Remigromig

Interventions

  • Remigromig is a humanized antibody formulated for IVT administration

    Also known as: EYE103

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)

    Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of \> or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

    Time frame: Up to approximately 12 weeks

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to approximately 12 weeks

  3. Number of Participants Who Experienced a Serious Adverse Event (SAE)

    An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

    Time frame: Up to approximately 24 weeks

  4. Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments

    Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

    Time frame: Baseline and Week 12

  5. Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants

    Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

    Time frame: Baseline and Week 12

  6. Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants

    Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants

    Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

    Time frame: Baseline and Week 12

  2. Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants

    Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

    Time frame: Baseline and Week 12

  3. Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants

    SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

    Time frame: Baseline and 12 weeks

  4. Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants

    SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

    Time frame: Baseline and 12 weeks

  5. Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants

    Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

    Time frame: Baseline and Week 12

  6. Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants

    Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

    Time frame: Baseline and Week 12

  7. Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants

    Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

    Time frame: Baseline and Week 12

  8. Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants

    Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

    Time frame: Baseline and Week 12

07

Results

Posted Sep 29, 2026

Participant flow

This study consisted of two parts. Part 1, the multiple ascending dose (MAD) phase, evaluated escalating doses of remigromig (EYE103) in participants with treatment-naive diabetic macular edema (DME) and in participants with neovascular age-related macular degeneration (NVAMD). Part 2 compared two selected remigromig doses and was planned to enroll participants with DME and NVAMD (both treatment-naïve and previously treated); however, no participants with NVAMD were enrolled.

Participant flow — Overall Study
MilestonePart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mg
Started333311100000
Received additional remigromig injections0021330000
Participants with dme032211100000
Participants with nvamd3011000000
Completed33331090000
Not completed0000110000
Withdrew: Withdrawal by subject0000110000

Outcome measures

SecondaryNumber of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants—01042
SecondaryNumber of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants0—00——
SecondaryMean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · μm
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
μmPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants—-120 ± 97.51-251 ± 39.60-162 ± 43.13-131 ± 68.13-144 ± 151.28
SecondaryMean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · μm
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
μmPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants-277 ± 176.67—-149 ± NA-363 ± NA——
SecondaryNumber of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants0000000
SecondaryNumber of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants0—00——
SecondaryPercent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Time frame:
Baseline and Week 12
Reported as:
Mean · Percentage change from baseline
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Percentage change from baselinePart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants—77.19 ± 51.40492.08 ± 8.35060.66 ± 34.89281.84 ± 12.36481.00 ± 39.177
SecondaryPercent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Time frame:
Baseline and Week 12
Reported as:
Mean · Percentage change from baseline
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Percentage change from baselinePart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants187.41 ± 121.251—133.04 ± NA109.67 ± NA——
PrimaryNumber of Participants Who Experienced a Dose-limiting Toxicity (DLT)

Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of \> or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

Time frame:
Up to approximately 12 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)000000
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to approximately 12 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants Who Experienced an Adverse Event (AE)212354
PrimaryNumber of Participants Who Experienced a Serious Adverse Event (SAE)

An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

Time frame:
Up to approximately 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Serious Adverse Event (SAE)
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants Who Experienced a Serious Adverse Event (SAE)000001
PrimaryNumber of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments

Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
ParticipantsPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments000000
PrimaryMean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Time frame:
Baseline and Week 12
Reported as:
Mean · Change in ETDRS letters
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Change in ETDRS lettersPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants—5.3 ± 1.5314.5 ± 2.1210.0 ± 5.614.1 ± 6.749.9 ± 8.42
PrimaryMean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Time frame:
Baseline and Week 12
Reported as:
Mean · Change in ETDRS letters
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Change in ETDRS lettersPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mg
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants6.7 ± 2.52—14.0 ± NA0.0 ± NA——

Adverse events

Collected over Up to approximately 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Remigromig 0.05 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
Part 1: Remigromig 0.15 mg0/3 (0%)0/3 (0%)1/3 (33.3%)
Part 1: Remigromig 0.48 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
Part 1: Remigromig 0.8 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg0/11 (0%)0/11 (0%)5/11 (45.5%)
Part 2: Remigromig DME 0.8 mg0/10 (0%)1/10 (10%)4/10 (40%)
Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg———
Part 2: Remigromig NVAMD 0.8 mg———
Part 2: Remigromig Experienced NVAMD 0.48 mg———
Part 2: Remigromig Experienced NVAMD 0.8 mg———
Most frequent serious events
Most frequent serious events
EventPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mg
OsteomyelitisInfections and infestations0/30/30/30/30/111/10————
Staphylococcal bacteraemiaInfections and infestations0/30/30/30/30/111/10————
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPart 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart 1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mg
AsthenopiaEye disorders1/30/30/30/30/110/10————
CataractEye disorders0/30/30/31/30/110/10————
Conjunctival haemorrhageEye disorders0/31/30/30/31/110/10————
Diabetic retinopathyEye disorders0/30/31/30/30/110/10————
Eye PainEye disorders1/30/30/30/30/110/10————
Ocular hypertensionEye disorders0/31/30/30/30/110/10————
Retinal haemorrhageEye disorders0/30/30/31/30/110/10————
Vision blurredEye disorders1/30/30/30/30/110/10————
Vitreous floatersEye disorders1/30/30/30/30/110/10————
Sensation of foreign bodyGeneral disorders1/30/30/30/30/110/10————

Baseline characteristics

Two cohorts of treatment-naïve NVAMD participants, and 2 cohorts of treatment-experienced participants were planned to be included in Part 2 of this study, however, no participants with NVAMD were enrolled in part 2 of this study

Age, Continuous
Age, Continuous(Years)Part 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mgTotal
Mean79.0 ± 15.1366.3 ± 7.3766.3 ± 15.5360.0 ± 12.2962.0 ± 6.2958.1 ± 6.79————63.0 ± 10.12
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mgTotal
Female322052000014
Male011368000019
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Part 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mgTotal
Count of participants——————————0
Best-corrected Visual Acuity (BCVA) at Baseline
Best-corrected Visual Acuity (BCVA) at Baseline(ETDRS Letters)Part 1: Remigromig 0.05 mgPart 1: Remigromig 0.15 mgPart 1: Remigromig 0.48 mgPart1: Remigromig 0.8 mgPart 2: Remigromig Diabetic Macular Edema (DME) 0.48 mgPart 2: Remigromig DME 0.8 mgPart 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mgPart 2: Remigromig NVAMD 0.8 mgPart 2: Remigromig Experienced NVAMD 0.48 mgPart 2: Remigromig Experienced NVAMD 0.8 mgTotal
Mean50.7 ± 14.0153.7 ± 9.7156.3 ± 8.5048.7 ± 11.1561.4 ± 5.0861.5 ± 6.60————58.1 ± 8.59
08

Study locations

32 sites
  • Phoenix, AZ
    Phoenix, Arizona 85032, United States
  • Bakersfield, CA
    Bakersfield, California 93309, United States
  • Modesto, CA
    Modesto, California 95356, United States
  • Mountain View, CA
    Mountain View, California 94040, United States
  • Sacramento, CA
    Sacramento, California 95825, United States
  • Sacramento, CA
    Sacramento, California 95841, United States
  • Colorado Springs, Colorado
    Colorado Springs, Colorado 80909, United States
  • Lakewood, CO
    Lakewood, Colorado 80288, United States
  • Pompano Beach
    Pompano Beach, Florida 33064, United States
  • Lemont, NV
    Lemont, Illinois 60439, United States
  • Hagerstown, MD
    Hagerstown, Maryland 21740, United States
  • Reno, NV
    Reno, Nevada 89502, United States
  • West Columbia, SC
    West Columbia, South Carolina 29169, United States
  • Germantown, TN
    Germantown, Tennessee 38138, United States
  • Knoxville, TN
    Knoxville, Tennessee 37922, United States
  • Nashville, TN
    Nashville, Tennessee 37203, United States
  • Abilene, TX
    Abilene, Texas 79606, United States
  • Amarillo, TX
    Amarillo, Texas 79109, United States
  • Austin, TX
    Austin, Texas 78705, United States
  • Bellaire, TX
    Bellaire, Texas 77401, United States
  • Dallas, TX
    Dallas, Texas 75231, United States
  • Katy, TX
    Katy, Texas 77494, United States
  • McAllen, TX
    McAllen, Texas 78503, United States
  • Plano, TX
    Plano, Texas 75075, United States
  • Round Rock, TX
    Round Rock, Texas 78681, United States
  • San Antonio, TX
    San Antonio, Texas 78240, United States
  • The Woodlands, TX
    The Woodlands, Texas 77384, United States
  • Ciudad Autonoma Buenos Aires
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1121ABB, Argentina
  • Caba, Argentina
    Caba, 1023, Argentina
  • Arecibo, PR
    Arecibo, PR 00612, Puerto Rico
  • London, England
    London, England NW10 7NS, United Kingdom
  • London, UK
    London, W1G7LB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2024, 14 months.

Results were first posted in Sep 2026, 2 years 1 month after primary completion. A results delay was requested in Aug 2024.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 26, 2023
StartActual
Jun 12, 2023
Primary completionActual
Aug 26, 2024
CompletionActual
Aug 26, 2024
Results delay requested
Aug 26, 2024
Results first posted
Sep 29, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Sep 29, 2026 · revised Nov 3, 2026
Interventions
Changed EYE103→Remigromig
Nov 3, 2026
Primary outcomes
6 added, 1 removed
What changed in the outcomes
  • AddedNumber of Participants Who Experienced a Dose-limiting Toxicity (DLT)Time frame: Up to approximately 12 weeks
  • AddedNumber of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 12 weeks
  • AddedNumber of Participants Who Experienced a Serious Adverse Event (SAE)Time frame: Up to approximately 24 weeks
  • AddedNumber of Participants Who Experienced Clinically Meaningful Changes in Laboratory AssessmentsTime frame: Baseline and Week 12
  • AddedMean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME ParticipantsTime frame: Baseline and Week 12
  • AddedMean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD ParticipantsTime frame: Baseline and Week 12
  • RemovedAdverse EventsTime frame: 3 months
Sep 29, 2026
Documents
Secondary outcomes
8 added, 1 removed
What changed in the outcomes
  • AddedNumber of Participants With ETDRS BCVA Response- Treatment-Naive DME ParticipantsTime frame: Baseline and Week 12
  • AddedNumber of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD ParticipantsTime frame: Baseline and Week 12
  • AddedMean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME ParticipantsTime frame: Baseline and 12 weeks
  • AddedMean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD ParticipantsTime frame: Baseline and 12 weeks
  • AddedNumber of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME ParticipantsTime frame: Baseline and Week 12
  • AddedNumber of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD ParticipantsTime frame: Baseline and Week 12
  • AddedPercent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME ParticipantsTime frame: Baseline and Week 12
  • AddedPercent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD ParticipantsTime frame: Baseline and Week 12
  • RemovedBest-corrected Visual AcuityTime frame: 3 months
Sep 29, 2026
Title
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Posted results revised
    Interventions Changed EYE103→Remigromig
    Title A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
    + 2 other changes: verification date and description
  2. Sep 29, 2026
    Results posted
    Primary outcomes 6 added, 1 removed
    What changed in the outcomes
    • AddedNumber of Participants Who Experienced a Dose-limiting Toxicity (DLT)Time frame: Up to approximately 12 weeks
    • AddedNumber of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 12 weeks
    • AddedNumber of Participants Who Experienced a Serious Adverse Event (SAE)Time frame: Up to approximately 24 weeks
    • AddedNumber of Participants Who Experienced Clinically Meaningful Changes in Laboratory AssessmentsTime frame: Baseline and Week 12
    • AddedMean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME ParticipantsTime frame: Baseline and Week 12
    • AddedMean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD ParticipantsTime frame: Baseline and Week 12
    • RemovedAdverse EventsTime frame: 3 months
    Secondary outcomes 8 added, 1 removed
    What changed in the outcomes
    • AddedNumber of Participants With ETDRS BCVA Response- Treatment-Naive DME ParticipantsTime frame: Baseline and Week 12
    • AddedNumber of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD ParticipantsTime frame: Baseline and Week 12
    • AddedMean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME ParticipantsTime frame: Baseline and 12 weeks
    • AddedMean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD ParticipantsTime frame: Baseline and 12 weeks
    • AddedNumber of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME ParticipantsTime frame: Baseline and Week 12
    • AddedNumber of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD ParticipantsTime frame: Baseline and Week 12
    • AddedPercent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME ParticipantsTime frame: Baseline and Week 12
    • AddedPercent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD ParticipantsTime frame: Baseline and Week 12
    • RemovedBest-corrected Visual AcuityTime frame: 3 months
    + 3 other changes: index terms, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05919693
Lead sponsor
EyeBiotech Ltd.
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Jun 12, 2023
Primary completion
Aug 26, 2024
Completion
Aug 26, 2024
Results posted
Sep 29, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remigromig

Start the discussion